<DOC>
	<DOC>NCT01627132</DOC>
	<brief_summary>The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on dasatinib.</brief_summary>
	<brief_title>Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Chronic Myeloid Leukemia in the Chronic Phase. Patients with BCRABLnegative checks. 15 years old over. ECOG performance status (PS) score 02. Adequate organ function (hepatic, renal and lung). Signed written informed consent. A case with the double cancer of the activity. Women who are pregnant or breastfeeding. Patients with complications or a history of severe. Patients with mutation of T315I、F317L、V299L. Patients with additional chromosome abnormalities. The case of Pleural effusion with poor control. Patients with a history of hematopoietic stem cell transplantation.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>